The Impact of a Suspicious Prostate Biopsy on Patients' Psychological, Socio-behavioral, and Medical Care Outcomes
Overview
Authors
Affiliations
Objective: To evaluate the psychological, socio-behavioral, and medical implications of apparently false-positive prostate cancer screening results.
Methods: One hundred and twenty-one men with a benign prostate biopsy performed in response to a suspicious screening test (biopsy group) and 164 men with a normal prostate-specific antigen (PSA) test result (normal PSA group) responded to a questionnaire 6 weeks, 6 and 12 months after their biopsy or PSA test.
Results: The mean (+/-SD) age of respondents was 61+/-9 years (range, 41 to 88 years). One year later, 26% (32/121) of men in the biopsy group reported having worried "a lot" or "some of the time" that they may develop prostate cancer, compared with 6% (10/164) in the normal PSA group (P<.001). Forty-six percent of the biopsy group reported thinking their wife or significant other was concerned about prostate cancer, versus 14% in the normal PSA group (P<.001). Medical record review showed that biopsied men were more likely than those in the normal PSA group to have had at least 1 follow-up PSA test over the year (73% vs 42%, P<.001), more likely to have had another biopsy (15% vs 1%, P<.001), and more likely to have visited a urologist (71% vs 13%, P<.001).
Conclusion: One year later, men who underwent prostate biopsy more often reported worrying about prostate cancer. In addition, there were related psychological, socio-behavioral, and medical care implications. These hidden tolls associated with screening should be considered in the discussion about the benefits and risks of prostate cancer screening.
Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer.
Gogola S, Rejzer M, Bahmad H, Alloush F, Omarzai Y, Poppiti R Cancers (Basel). 2023; 15(5).
PMID: 36900412 PMC: 10000420. DOI: 10.3390/cancers15051621.
Estimating the lifetime risk of a false positive screening test result.
White T, Algeri S PLoS One. 2023; 18(2):e0281153.
PMID: 36791062 PMC: 9931091. DOI: 10.1371/journal.pone.0281153.
Logozzi M, Mizzoni D, Di Raimo R, Giuliani A, Maggi M, Sciarra A Front Oncol. 2021; 11:727317.
PMID: 34745949 PMC: 8564386. DOI: 10.3389/fonc.2021.727317.
Decision fatigue in low-value prostate cancer screening.
Hunt T, Ambrose J, Haaland B, Kawamoto K, Dechet C, Lowrance W Cancer. 2021; 127(18):3343-3353.
PMID: 34043813 PMC: 8497012. DOI: 10.1002/cncr.33644.
Measuring inter-individual differences in stress sensitivity during MR-guided prostate biopsy.
Kohn N, Heidkamp J, Fernandez G, Futterer J, Tendolkar I Sci Rep. 2021; 11(1):2454.
PMID: 33510379 PMC: 7844251. DOI: 10.1038/s41598-021-82199-z.